1. Home
  2. DOGZ vs TPST Comparison

DOGZ vs TPST Comparison

Compare DOGZ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DOGZ

Dogness (International) Corporation

HOLD

Current Price

$1.22

Market Cap

13.6M

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.20

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOGZ
TPST
Founded
2003
2011
Country
China
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6M
15.6M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
DOGZ
TPST
Price
$1.22
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
678.4K
210.6K
Earning Date
04-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$0.84
52 Week High
$16.59
$12.22

Technical Indicators

Market Signals
Indicator
DOGZ
TPST
Relative Strength Index (RSI) 68.44 64.98
Support Level $0.87 $1.02
Resistance Level $1.32 $2.48
Average True Range (ATR) 0.11 0.08
MACD 0.04 0.05
Stochastic Oscillator 65.39 80.95

Price Performance

Historical Comparison
DOGZ
TPST

About DOGZ Dogness (International) Corporation

Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: